Evolving management of colorectal cancer

Jochem van der Voort van Zijp, Harald J Hoekstra, Marc D Basson

Abstract
This article reviews recent advances in surgical techniques and adjuvant therapies for colorectal cancer, including total mesorectal excision, the resection of liver and lung metastasis and advances in chemoradiation and foreshadows some interventions that may lie just beyond the frontier. In particular, little is known about the intracellular and extracellular cascades that may influence colorectal cancer cell adhesion and metastasis. Although the phosphorylation of focal adhesion kinases and focal adhesion associated proteins in response to integrin-mediated cell matrix binding (“outside in integrin signaling”) is well described, the stimulation of cell adhesion by intracellular signals activated by pressure prior to adhesion represents a different signal paradigm. However, several studies have suggested that increased pressure and shear stress activate cancer cell adhesion. Further studies of the pathways that regulate integrin-driven cancer cell adhesion may identify ways to disrupt these signals or block integrin-mediated adhesion so that adhesion and eventual metastasis can be prevented in the future.

INCIDENCE AND PREVALENCE
Colorectal cancer is the third most common cancer and the third leading cause of cancer related mortality in the United States[5]. Colorectal cancer is also very common in Western Europe, Australia and New Zealand, whereas the age standardized incidence rate of colorectal carcinoma is very low in India and Africa[6]. There seems to be an association of higher incidence rates in colorectal cancer with increasing affluence[7]. Over the past decade, colorectal cancer rates have modestly decreased or remained level. Until age 50, men and women have similar incidence and mortality rates; after age 50, men are more vulnerable[8].

Peer reviewer: Javier San Martin, Chief, Gastroenterology and Endoscopy, Sanatorio Cantegril, Av. Roosevelt y P 13, Punta del Este 20100, Uruguay

van der Voort van Zijp J, Hoekstra HJ, Basson MD. Evolving management of colorectal cancer. World J Gastroenterol 2008; 14(25): 3956-3967 Available from: URL: http://www.wjgnet.com/1007-9327/14/3956.asp DOI: http://dx.doi.org/10.3748/wjg.14.3956

© 2008 The WJG Press. All rights reserved.
women in the Netherlands have a 4.67% and 3.34% cumulative incidence to develop colorectal cancer[10]. By the age of 70 years, at least 50% of the western population will develop some form of colorectal tumor, spanning the spectrum from an early benign polyp to an invasive adenocarcinoma.

**STAGE OF COLORECTAL DISEASE**

The stage of disease is one of the most important prognostic factors for survival in patients with colorectal cancer. It is therefore clinically significant to know the relative incidence for each stage of the disease. The incidence of Stage I disease in the United States has increased over the past years due to better screening and is currently around 30%. This is an important development since the detection of early stage disease increases the chance for R0 resection and potential cure for colorectal cancer. The incidence of Stage II and III disease are respectively 27% and 24%, while Stage IV disease is present in 19% of patients in the United States. A remarkable observation is that older patients are diagnosed more frequently at an early stage (Stage 0 and I) and diagnosed three times less frequently with stage IV disease than younger patients. A possibility is that younger patients feel less at risk and ignore symptoms for a longer period of time and are therefore diagnosed at a later stage[12].

The relative 5-year survival rates in the United States show that when the disease is detected early, at a localized stage, survival rates for Stage I colon and rectal cancer are 93% and 92%, respectively. At Stage II disease the 5-year survival rates are between 72%-85% for colon cancer and between 56%-73% for rectal cancer. The fluctuations in Stage II survival rates are due to the fact that Stage II disease includes both T3 (Stage II A) and T4 (Stage II B) tumors. For more advanced disease at diagnosis, the survival rates drop significantly. At Stage III, the 5-year survival rates for colon and rectal cancer vary from 44%-83% and 30%-67% respectively. Again the wide range of survival rates reflects the fact that Stage III disease is further categorized into the following sub-categories, Stage III A (T1-2, N1, M0), Stage III B (T3-T4, N1, M0) and Stage III C (any T, N2, M0) disease. For Stage IV colorectal disease the 5-year survival rate may be as low as 8%[13,14].

**SURGICAL TREATMENT**

Surgical management is the primary treatment of potentially curable colorectal cancer. In most cases, this involves resection of the primary tumor and regional lymph nodes. However, treatment of curable colorectal cancer patients may vary from endoscopic polypectomy for malignant polyps or local excision in carefully selected patients with limited rectal carcinomas to multimodality management for locally advanced rectal cancers or cancers invading adjacent organs. The objective in all cases is to maximize both oncologic and functional results. Due to the improvements in surgical techniques, as well as better screening and new developments in adjuvant therapy, the ratio of people with potentially curable disease has increased over the past decades. This evolution has included the development of total mesorectal excision, the introduction of laparoscopic surgery, the sentinel lymph node technique, curative resections of liver and lung metastasis and improvements in adjuvant therapies such as chemotherapy and radiotherapy.

En bloc resection and the no-touch technique were first described in 1967 by Trumbell et al and remain valid and important[15]. The best prevention strategy of potential tumor cell distribution is maintained by the surgeon strictly using the principles of en-bloc resection. As the likelihood of lymph node involvement increases with depth of tumor invasion (5.6% for pT_1, 10% for pT_2, 36.7% for pT_3, and 77.7% for pT_4 colon carcinoma)[16], invasive adenocarcinomas require ligation and resection of the lymphovascular pedicle directly draining the intestinal segment containing the tumor. When the lesion is equidistant between two pedicles, then both should be encompassed in the resection. Another surgical option is the no-touch isolation technique with primary ligation of the corresponding vessels, and dissection of the lymph nodes[17-20]. The concept of this technique is to avoid tumor manipulation during surgery so that shedding of tumor cells into the lymphatic or vascular circulation is kept to a minimum. The presence of free cancer cells within the lymphatic, vascular circulation or in the peritoneal cavity can be detected by mRNA coding using qPCR and is associated with a poorer prognosis for patients undergoing curative colorectal cancer surgery[21,22]. However, there seems to be limited benefit in the no-touch isolation group; the morbidity and mortality rates after a 5-year follow-up of patients were equal[23]. More recently, a study by Hayashi et al has suggested that the no-touch isolation technique may be useful to prevent cancer cells from being shed into the portal vein during surgical manipulation[24].

Today, en-bloc resection without the primary ligation of corresponding vessels is still the more common technique.

Other advances in surgical techniques have resulted in less tumor recurrence and given patients with advanced colorectal disease the opportunity to undergo surgery with curative intent. In 1982 Heald developed an important surgical technique for the treatment of rectal cancer. The concept of total mesorectal excision (TME) was introduced in conjunction with low anterior resection (LAR) as a means of procuring all perirectal fat while facilitating sphincter preservation[25]. Recent studies have reported local recurrence rates of around 10% in various TME series[26-30]. In the study by Moore et al, local recurrence rates of less than 5% have been reported with a distal margin of 1 cm, provided that the mesorectum can be excised as a complete lymphovascular package[31]. Today TME has been successfully taught as a standardized procedure and translated to other colorectal surgical environments with reproducible cancer-specific outcomes[32].
Advances in laparoscopic equipment and technique have revolutionized the surgical approach to many diseases. Laparoscopic surgery for colorectal cancer is currently considered an acceptable alternative to open resection for colorectal cancer. There are small but measurable short term benefits such as decreased postoperative narcotic use, earlier return of bowel function, shorter length of stay and better cosmetic results. Today there is no question that laparoscopic surgery can be performed safely and effectively by experienced surgeons. There is enough evidence that survival rates are not compromised by the laparoscopic approach.

Although the first laparoscopic colon resection was reported in 1991, the adoption of minimally invasive colon resection has been impeded by several factors. First, laparoscopic colon surgery is technically demanding. Second, and more importantly, there has been historical concern about whether minimally invasive surgery for colonic malignancies would achieve adequate oncologic resection. The most recent studies, including retrospective and prospective registries, as well as comparative studies clearly demonstrate that oncologic principles are not compromised by laparoscopic techniques, and that the yield of lymph nodes, surgical margins (proximal, distal and radial), and length of bowel resected were comparable to open cancer surgery.

Another problem that has been discussed controversially is the issue of whether laparoscopic surgery is associated with an increased hematogenous and intraperitoneal tumor cell distribution. Some studies have shown that there is a higher incidence of intraperitoneal tumor cell dissemination during laparoscopic resection for colorectal cancer when compared to open surgery for colorectal cancer. On the other hand, other studies have contradicted this observation. Finally, another concern has been the incidence of port-site metastasis after laparoscopic resection. Although port-site metastases have not been restricted to laparoscopic surgery for colorectal cancer, the major impact of this phenomenon has been in this field. A closer look at the literature reveals most reports with a high incidence rate were small series published in the early 1990s. Within the last ten years, three large trials of laparoscopic surgery for colorectal cancer have been published that clearly demonstrated a low incidence of wound recurrence not statistically significantly increased compared to wound recurrence after open laparotomy. However, it should be cautioned that these trials were not adequately powered to fully address the question. Moreover, in the COST-trial, wound recurrence rates demonstrated an incidence of port site recurrence that, although both low and not statistically significantly different from that after open surgery, was nevertheless more than twice the rate of wound implantation seen after open surgery (0.5% incidence in the laparoscopic arm vs 0.2% in the open surgical arm of the trial). Although the question therefore still has not been completely addressed, it appears that the incidence is quite low and within acceptable clinical range, and it seems dubious that a randomized trial of sufficient size ever will be conducted to settle conclusively this issue. It seems likely that insufficient technical skills and experience at the beginning of the laparoscopic era contributed to the early reports that described considerably higher rates of port site recurrence.

Many cancers, including colorectal cancer, spread first to the lymph nodes before reaching other parts of the body. Lymph node status remains one of the most important prognostic factors in the management of colorectal cancer. In patients without nodal disease, recurrent tumors still develop in about 15% to 20% of cases within 5 years of diagnosis. The reasons for this are unclear, but may depend upon the quality of surgical resection and conventional pathologic review. Node-negative patients are usually not treated with adjuvant chemotherapy outside a clinical trial because of the lack of definitive evidence of survival benefit. Patients with nodal disease, on the other hand, should be treated with adjuvant chemotherapy because of potential reduction of mortality up to 33%. Therefore, it is critical to avoid pathological understaging of the specimen. Standard pathologic evaluation may overlook low volume nodal metastasis, thereby failing to identify nodes imperative to accurate staging. Inconsistencies in number of nodes harvested at time of pathologic processing impact significantly colon cancer staging accuracy. This nodal sampling error serves as the basis for guidelines establishing a 12 node minimum for adequate staging utilizing conventional techniques. Up to 78% of metastases are identified in subcentimeter nodes that may be overlooked during standard gross pathologic dissection of resected specimens. Microscopic examination of 1 or 2 hematoxylin and eosin-stained sections of a 5-mm node limits pathologic assessment to less than 1% of the entire node, making identification of small tumor cell aggregates challenging. In a study by Saha et al, sentinel lymph node mapping appears superior to conventional pathologic review and may therefore be a useful method to avoid understaging. Nodal positivity was 48% for the group assigned sentinel-lymph-node mapping, compared with 35% for the group assigned conventional staging. In this study, sentinel lymphatic mapping accounts for the upstaging of 13% of colon cancer. In other studies, sentinel lymph node mapping accounts for the upstaging of 10%-24% of patients. The consequence of upstaging is that these patients now become candidates for adjuvant chemotherapy. After a minimum of 2 years follow-up, patients assigned nodal mapping (n = 153) had an overall recurrence of 7%, compared with 25% (n = 162) for the patients assigned conventional staging (P = 0.001). As the sentinel lymph node technique has developed, some investigators describe over 90% success in identifying the sentinel node and accuracy rates of approximately 90% for patients without nodal disease. In patients with colorectal metastases, advances in surgical techniques have made it possible that the goal of surgery is no longer palliative but of curative intent. Therefore, a complication such as wound recurrence may have grave clinical consequences for patients that
are operated on with curative intent. It thus becomes increasingly important that surgeons minimize tumor spill into the peritoneal cavity or into the lymphatic/vascular systems during surgical procedures for colorectal cancer. If not, tumors may recur and compromise a potentially curative resection.

The liver is the most common site for colorectal metastasis, since the venous outflow of the gut first reaches the liver through the portal system before flowing back into the systemic circulation. Approximately one-third of patients diagnosed with colorectal cancer will develop synchronous or metachronous metastases to the liver. The incidence of synchronous metastasis has ranged from 23.0% to 46.8% and the 5-year survival rate after hepatic resection has been reported to be 14% to 40% in studies with more than 100 or more patients. Several studies have suggested that careful selection of patients for hepatic resection of colorectal metastases can result in favourable survival. A recent study by Rees et al found 7 risk factors (Basingstoke Prediction Index) that were found to be independent predictors of poor survival in a multivariate analysis. The 7 risk factors were number of hepatic metastases > 3, node positive primary, poorly differentiated primary, extraplastic disease, tumor diameter ≥ 5 cm, carcinoembryonic antigen level > 60 ng/mL, and positive resection margin. The first 6 of these criteria were used in a preoperative scoring system and the last 6 in the postoperative setting. Patients with the worst postoperative prognostic criteria had an expected median cancer-specific survival of 0.7 years and a 5-year cancer-specific survival of 2%. Conversely, patients with the best prognostic postoperative criteria had an expected median cancer-specific survival of 7.4 years and a 5-year cancer-specific survival of 64%. It is therefore very important to preoperatively assess if resection is achievable, most preferably with a 1 cm margin. It is often difficult to measure a 1 cm distance to the tumor edge on the specimen because of dissection or cautery artifact. Other times a surgical margin of 1 cm cannot be obtained because of the location of the tumor to the hepatic veins, portal veins, or vena cava. When tumor is left behind after surgery, meaning that RO resection is not achieved, the survival is not different than that in the nonresected group.

While surgical resection remains the gold standard of therapy, only a few patients are suitable candidates for curative surgical resection because of the presence of liver malignancy in unresectable locations, the number of and anatomic distribution of tumor lesions, or the presence of extrahepatic disease or poor liver function. An alternative treatment to control and potentially cure liver disease has been developed for use in patients with malignant liver tumors. Radiofrequency ablation (RFA), also known as “radiofrequency thermal ablation”, is a recently developed thermoablative technique. It induces temperature changes by using high-frequency alternating current applied via electrodes placed within the tissue to generate areas of coagulative necrosis and tissue desiccation. Overall recurrence for colorectal cancer was most common after RFA (84% vs 64% RFA and resection vs 52% resection only, P = 0.001). Thus, RFA has been reserved as an adjunctive tool to resection, when complete resection is not possible, either alone or in combination with resection. The study by Abdalla et al demonstrates that RFA alone or in combination with resection for unresectable patients does not provide survival comparable to resection, and provides survival only slightly superior to nonsurgical treatment.

After colorectal metastases to the liver, the lungs are the second most common site of metastasis. The number of possibly resectable cases of lung metastasis after primary surgery for colorectal cancer has increased considerably over the past 20 years. The typical pattern of lung metastasis is single or multiple nodules rather than miliary tumors or lymphangitis carcinomatosa. No effective chemotherapy regimen has been found for metastatic disease. Hence, a surgical procedure to eliminate pulmonary metastases is generally accepted as the only potentially curative treatment. In favor of surgery is the recent trend toward earlier detection of pulmonary metastases as small peripheral densities with increasingly common use of screening with spiral or high-resolution computed tomography. The reported 5-year survival rates for lung metastectomy surgery were 24% to 63%, and most were around 40%.

The criteria for resection of pulmonary metastases from colorectal carcinoma included unilateral or bilateral excisable lung lesions per preoperative chest radiography, no local recurrence of primary lesions, and no extrapoluminal lesions with the exception of associated prior or simultaneous resectable hepatic metastases. Elevated CEA level and the number of metastases are the most significant prognostic factors for overall survival after resection of lung metastases from colorectal cancer.

ADJUVANT THERAPY

For the treatment of rectal cancer, adjuvant radiotherapy has become a standard procedure. The following two schedules of treatment have been explored over the last decades: short term treatment that delivers 25 Gy in 5 fractions during 1 wk, followed immediately by surgery, and conventional schedules that deliver 40 Gy to 50 Gy in 20-25 fractions during 4 to 5 wk, followed by surgery 3-6 wk later. Regardless of the schedule, preoperative radiotherapy decreases local recurrence rates by 50%-60% when compared to surgery alone. The conventional schedules are delivered in combination with chemotherapy to patients with locally advanced rectum cancer (T3-T4 tumors and N+ disease). The radiobiological dose delivered in a short term treatment schedule is too low for adequate response in locally advanced rectal tumors. In 2001, a study by Marijnen et al demonstrated that short term treatment with 25 Gy during 1 wk did not achieve tumor down staging for T1-T3 tumors within a period of 10 d. However, a schedule of 50.4 Gy given over a period of 6 wk in combination with 5-FU and leucovorin did cause...
down staging of locally advanced rectum tumors. Today the standard treatment for locally advanced rectum carcinoma is pre-operative radiotherapy in combination with 5-FU and leucovorin. In addition, it has been demonstrated that timing of chemoradiation for locally advanced tumors is important, since less toxicity and better local control may be achieved when chemoradiation is given pre-operatively instead of post-operatively. Thus far, there has been no conclusive demonstration of a gain in overall survival for patients with locally advanced rectum tumors treated with adjuvant chemoradiation.

During the past years, various phase I and II trials have been performed with capecitabine. It is a form of chemotherapy that is administered orally and is a tumor activated fluoropyrimidine carbonate. During the last of three enzymatic processes, thymidine phosphorylase converts capecitabine to 5-FU. The enzyme thymidine phosphorylase is found in high concentrations in rectal tumors and it is therefore less likely that healthy tissue within the radiation field is subjected to 5-FU. The advantages of this form of therapy are less toxicity, oral administration, and less chance of infections since a venous port access catheter is no longer necessary. Although the phase II trials with capecitabine in combination with radiotherapy for locally advanced rectum tumors show promising results, there are currently no phase III trials that give information about local recurrence during a long term follow-up period. However, the National Surgical Breast and Bowel Project trail in the United States is planning on performing such a study in the near future. If the results from this study show acceptable local recurrence rates, then capecitabine may replace the 5-FU/leucovorin schedule. A study by Kim et al suggests that the addition of leucovorin to capecitabine does not work synergistically but actually seems more toxic. For this reason a combined capecitabine and leucovorin schedule does not seem desirable. Other phase I and II studies have tried to combine capecitabine with oxaliplatin. The results seem promising as well, and grade III/IV toxicity does not seem greater than the capecitabine and 5-FU/leucovorin schedules. Although there are many new developments, 5-FU and leucovorin in combination with radiotherapy remains the standard of neo-adjuvant treatment in most countries for patients with locally advanced rectum carcinoma.

Although research efforts continue to be directed at deriving new cytotoxic and antiproliferative agents directed specifically at cancer cells, the concept of targeting the angiogenic support of tumors has recently become of interest, and angiogenesis inhibitors have also been introduced for treatment of cancer. Bevacizumab is an anti-VEGF antibody. When combined with conventional chemotherapy, this agent has been reported to prolong survival in patients with advanced colorectal cancer treated in a palliative setting. Additionally, recent trials with neo-adjuvant chemotherapy suggest that irresectable liver metastases can be downstaged with this agent. Thus, an increasing number of patients with colorectal metastases to the liver may now become candidates for liver resection. Indeed, in such patients preoperative treatment with bevacizumab and chemotherapy may be associated with less blood loss compared to chemotherapy alone. If bevacizumab and chemotherapy are discontinued at least 8 wk before hepatic resection, the addition of bevacizumab to preoperative irinotecan and oxaliplatin does not increase morbidity after hepatic resection. Unfortunately, there are no studies yet that compare whether the combination of bevacizumab and chemotherapy allows for better downstaging of liver metastases than conventional chemotherapy alone. This will be an important subject for future study, as will the long term outcomes of patients downstaged with these agents and then subjected to liver resection of the remaining obvious metastases.

Despite all of these advances in surgical techniques and adjuvant therapies, colorectal tumor recurrence remains a problem. Manfredi et al described a 5-year cumulative rate of local recurrence of 12.8% and a 25.6% per cent rate of distant metastases. During surgery it is important that tumor free margins of the resected specimen are achieved and that tumor spill is avoided. Unfortunately, some tumor spill occurs in approximately half of patients that are operated for colorectal cancer. Many research studies have provided evidence for direct implantation of the tumor site or surgical wound by exfoliated cancer cells, hematogenous seeding, tissue manipulation, serolization by pneumoperitoneum, patient's positioning and immune dysfunction as potentially etiologic factors. Approximately 0.2%-1% of patients will eventually develop wound recurrence. Many of these patients also exhibit more diffuse peritoneal recurrence, although approximately half exhibit isolated wound recurrence. Either phenomenon has a negative impact on survival for those patients that are operated with curative intent. Since more than 80% of patients with colorectal disease are initially operated with curative intent, a complication such as wound or peritoneal recurrence may drastically influence their 5-year survival rate in a negative manner.

TUMOR CELL ADHESION

The contrast between the high rates of tumor cell spillage and circulating tumor cells and the much lower rates of clinical tumor metastasis or implantation after surgery suggests that tumor implantation may be regulated in some way. The mechanisms that determine which tumor cells adhere to target organs and tissues are poorly understood. Normally, if a cell is unable to attach to the extracellular matrix, it dies through induction of the cell suicide program known as apoptosis. Cancer cells, however, develop a means to avoid death in this situation. Cells that have suffered irreparable DNA damage activate specific proteases and nucleases that destroy the proteins and DNA of the cell, thereby effectively limiting the spread of potentially deleterious mutations. Cancer cells often exhibit mutations in genes...
involved in regulating this pathway.

Since not all cancer cells that are shed into the peritoneal cavity undergo apoptosis, there is always a possibility that these cells will eventually cause wound metastasis. Tumor implantation begins with the adhesion of tumor cells to the matrix proteins in the wound. The extracellular matrix consists chiefly of type I and IV collagens, laminins, heparin sulfate proteoglycan, fibronectin, and other noncollagenous glycoproteins. Cell adhesion to extracellular matrix proteins is mediated by diverse receptors, most notably by members of the integrin family. Integrons, heterodimeric transmembrane proteins, are composed of noncovalently associated alpha and beta subunits that define the integrin-ligand specificity, and their pattern of expression is likely to promote specific cellular adhesions. Both the physiologic status of the cell and divalent extracellular divalent cation concentrations can influence the affinity between integrins and their ligands. After adhesion of the cell, proliferation and angiogenesis are then required to support tumor growth, invasion and subsequent metastasis.

Treatments to prevent wound or peritoneal metastasis

During the past years not much progress has been booked in reducing wound recurrence in patients with curable colorectal cancer. The application of topical ointments, abdominal irrigation and port-site resection of wounds have had limited success. The most promising results to date are probably the studies that investigate the anticancer effect of COX-2 inhibitors. Various studies have shown that COX-2 inhibitors have both antiangiogenic and apoptotic effects on human colon cancer cells. A more recent study demonstrated that COX-2 inhibitors down-regulated β1-integrin expression, with consequent impairment of the ability of colon cancer cells to adhere to and migrate on extracellular matrix in an in vitro study. It is therefore possible that these drugs may reduce wound recurrence since they may interfere with the adhesion of the cell to extracellular matrix. However, to date, the mechanisms of drug action and interaction are still far from clear, and their roles within the clinical setting are yet to be observed. It is therefore important to further investigate factors that may be of significance during wound implantation and eventual tumor formation.

Extracellular influences on colon cancer cell adhesion

Interaction between cells and the extracellular matrix are in large part mediated by integrins in divalent cation-dependent processes. This means that extracellular processes that alter divalent cation concentrations may also influence colon cancer cell adhesion to the extracellular matrix. Local shifts in the concentrations of extracellular Mg$^{2+}$ and Ca$^{2+}$ occur during wound healing, impacting the function of divalent cation-dependent cell surface molecules responsible for cell-cell and cell-extracellular matrix interactions. Early in the process, when cell migration into the wound is initiated, Mg$^{2+}$ is elevated and Ca$^{2+}$ is reduced. As wound healing progresses, wound concentrations of Mg$^{2+}$ and Ca$^{2+}$ return to normal plasma levels. Ebert et al reported that Mn$^{2+}$ and Mg$^{2+}$ stimulate binding of HT-29 colon cancer cells to extracellular matrix proteins, and similar effects have been described in SW 620 and Caco-2 human colon cancer cells. However, calcium inhibits adhesion of SW 620 and Caco-2 human colon cancer cells to collagen I, which is the dominant collagen of the interstitial matrix. Furthermore, Mg$^{2+}$ and Mg$^{2+}$ potentiate cancer cell adhesion to murine surgical wounds and subsequent tumor development. In contrast, Ca$^{2+}$ inhibits cancer cell adhesion to murine surgical wounds and subsequent tumor development. The biological and chemotherapeutic response characterization of transplantable mouse colon tumors suggests that they are reasonable models for colon cancer in humans. Although more studies are required, these results raise the possibility that in the future, manipulation of divalent cation concentrations in irrigation of the surgical site may diminish perioperative tumor implantation.

Effects of physical forces on colon cancer cell adhesion

Cancer cells are subjected to pressure during surgical manipulation and passage through the venous and lymphatic system. Cells that are shed into the peritoneal cavity postoperatively are also subjected to increased pressure from postoperative edema. Surgical manipulation during either laparoscopic or open procedures is likely to result in the direct application of much higher pressures to tumors or lymphatic channels containing malignant cells. For instance, during laparoscopic colectomy for cancer, intra-abdominal pressure is often increased by 15 mmHg as the abdominal cavity is expanded to provide room to operate. The pressure engendered by a surgical forceps grasping tissue may be as high as 1500 mmHg. Normal portal venous pressures may be as high as 10 mmHg, and this may increase substantially in portal hypertension. Mesenteric venous pressures may exceed 50 mmHg during ocular manipulation during enucleation. Normal portal venous pressures may exceed this under normal circumstances to generate portal flow and might be accentuated by intra-abdominal pressure generated by ascites, Valsalva maneuvers, or bowel edema after surgery. Mesenteric lymphatic pressures in the setting of tumor infiltration into the lymphatics are unclear but might also be expected to be of similar orders of magnitude. Tumor cells in the systemic arterial circulation, of course, are exposed to substantially higher pressures.

Physical forces such as shear stress, and pressure have been reported to affect colon cancer cells. Increasing ambient pressure and the application of shear stress increased cell adhesion of several colon cancer cell lines and primary human colon cancer cells isolated directly from surgical specimens. Indeed, an increase of
15 mmHg above ambient pressure had a maximum effect on colon cancer cell line adhesion in vitro\(^1\). An interesting observation is that during colorectal cancer surgery cells are shed into the abdominal cavity and subjected to increases in shear during irrigation and increased pressure during and after surgical procedures. Such increases in pressure may enhance the adhesion of shed cells to surgical sites. Although these original studies were performed in vitro, 30 min exposure to 15 mmHg increased pressure has more recently been demonstrated to increase cancer cell adhesion to murine surgical wounds\(^3\) and to adversely affect survival in a murine transplantable tumor model\(^4\). There are obviously manifest differences between transplantable tumors in mice and the pathophysiology of human colon cancers, but as these same signal events have also been described in primary human colon cancer cells\(^5\), the animal data are suggestive that the same pathway might affect the development of metastatic tumors in humans.

The effect of pressure on focal adhesion-associated proteins

If pressure and shear stimulate the adhesion of cancer cells\(^6\), it may then be important to unravel the intracellular mechanisms that mediate this effect so that interventions can ultimately be targeted to prevent cancer cell adhesion. In many cells, the focal adhesion kinase FAK transduces signals after adhesion through association with the cytoplasmic domains of integrin subunits\(^7\). However, “inside-out signaling” by which intracellular events modulate integrin function is less well understood. A study by Cooke et al suggests that mechanical stimulation of enterochromaffin-derived BON cells directly or indirectly stimulates a G protein-coupled receptor that activates Gαq, mobilizes intracellular calcium, and causes 5-HT release\(^8\). Although this study did not portray increased adhesion due to mechanotransduction, it did show that shear stress on carcinoid cells activate an intracellular cascade that releases 5-HT. Consistent with such force-activated intracellular signaling, Thamilselvan et al demonstrated that extracellular pressure may increase integrin affinity and promote colon cancer adhesion in vitro via actin-dependent inside-out FAK and Src signals\(^9\). Indeed, it is likely that the intracellular cascade involved in colon cancer cell adhesion to extracellular matrix is very complex. Recently, the activation of PI 3-kinase/Akt signaling pathway has been correlated with prostatic malignancy\(^10\), colon cancer cell invasion\(^11\) and postoperative growth\(^12\). The overexpression of the PI 3-kinase/Akt pathway has also been described in human cancers including ovarian and colonic carcinomas\(^13\). Recent studies suggest that the PI 3-kinase/Akt pathway may also be required for pressure-stimulated cancer cell adhesion\(^14\), acting specifically via Akt-1\(^15\).

Several key structural proteins also seem to be involved in the mechanotransduction pathway, including cytoskeletal elements\(^16\), the adapter proteins Paxillin\(^17\) and alpha actinin-1\(^18\). Both Paxillin and alpha actinin-1 facilitate focal adhesion formation and physically link integrin-associated focal adhesion complexes with the cytoskeleton. These focal adhesion associated proteins are often abnormally expressed or mutated in cancer cells\(^19\). Therefore, they may be important in tumor biology in general. Although these focal adhesion associated proteins are not kinases themselves, these proteins facilitate the interaction of various kinases and other proteins required for this pathway to function. This makes them a promising target to uncouple the pathway required for force-activated adhesion without actually inhibiting cellular kinases, possibly leading to fewer side effects. Indeed, in a preliminary proof of principle, knockout of alpha actinin-1 has been shown to abolish the effect of pressure on tumor-free survival in a murine transplantable tumor model\(^4\).

CONCLUSION

Over the past decades, screening for colorectal neoplasm has shown to be critical for prevention, early diagnosis, downstaging, and improved survival. Beyond intensified screening programs, surgical techniques have evolved over the past years. Total mesorectal excision has improved survival rates for rectal cancer\(^20\). Other major advances have included liver and lung resections for patients with colorectal metastasis, so that at least some of these patients are no longer candidates for palliative treatment but instead can be treated with curative intent. Besides improvements in surgical techniques, adjuvant therapies such as radiotherapy and chemotherapy also have undergone improvement. At this moment, sentinel lymph node mapping is a technique that lies on the frontier, as does the proper role of anti-angiogenesis agents. Some studies suggest that the sentinel lymph node technique may upstage a significant number of patients who then become candidates for chemotherapy, while anti-angiogenic therapy may downstage patients who then become candidates for surgical resection of known metastases. However, before conclusions are made on these points, further follow-up of patient cohorts will be necessary. The cellular biochemistry involved in metastasis currently lies beyond the frontier. Unfortunately, little is known about the intracellular and extracellular cascades that may influence colorectal cancer cell adhesion and metastasis. Several studies have suggested that increased pressure and shear stress activate cancer cell adhesion. Further studies of the pathways that regulate integrin-driven cancer cell adhesion may identify ways to disrupt these signals or block integrin-mediated adhesion so that perioperative adhesion and eventual metastasis can be prevented in the future, adding yet another strategy to combat colorectal malignancy.

REFERENCES

1. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-1371
2 Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168

3 Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560

4 Lieberman DA, Weiss DG, Harford WV, Ahnen DJ, Provenzale D, Sontag SJ, Schnell TG, Chejfec G, Campbell DR, Kidao J, Bond JH, Nelson DB, Triadafilopoulos G, Ramirez FC, Collins JF, Johnston TK, McQuaid KR, Garewal H, Sampiner RE, Esquivel R, Robertson D. Five-year colon surveillance after screening colonoscopy. Gastroenterology 2007; 133: 1077-1085

5 National Cancer Institute. A snapshot of Colorectal Cancer 2005, 2007

6 Parkin DM, Stiller CA, Nectoux J. International variations in the incidence of childhood bone tumours. Int J Cancer 1993; 53: 371-376

7 Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell.

8 Wilminck AB. Overview of the epidemiology of colorectal cancer. Dis Colon Rectum 1997; 40: 483-493

9 Faby B, Bold RJ. Epidemiology and molecular genetics of colorectal cancer. Surg Oncol 1998; 7: 115-123

10 Vereniging van Integrale Kankercentra. Aantal nieuwe patiënten, leeftijdssverdeling, percentage kankerpatiënten en risico, 2007

11 Koningin Wilhelmina Fonds. Cijfers over dikke darmkanker, 2006

12 Damjanov N, Merope NL. Oral therapy for colorectal cancer: how to choose. Oncology (Williston Park) 2000; 14: 799-807; discussion 807-808, 813-814.

13 O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1405-1425

14 Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncol Res 2003; 8: 541-552

15 Turnbull RB Jr, Kyle K, Watson FR, Spratt J. Cancer of the colon: the influence of the no-touch isolation technic on survival rates. Ann Surg 1967; 166: 420-427

16 Hida J, Yasutomi M, Maruyama T, Fujimoto K, Uchida T, Okuno K. The extent of lymph node dissection for colon carcinoma: the potential impact on laparoscopic surgery. Cancer 1997; 80: 188-192

17 Bruch HP, Schwanderer O, Keller R. [Limitations of laparoscopic visceral surgery in oncology] Chirurg 2003; 74: 290-300

18 Bruch HP, Schwanderer O, Schiedek TH, Roblick UJ. Actual standards and controversies on operative technique and lymph-node dissection in colorectal cancer. Langenbecks Arch Surg 1999; 384: 167-175

19 Schwindacher T, Schiedek TH, Killaitis C, Bruch HP. A case-control-study comparing laparoscopic versus open surgery for rectosigmoidal and rectal cancer. Int J Colorectal Dis 1999; 14: 158-163

20 Wiggers T, Jeekel J, Arends JW, Brinkhorst AP, KluckHM, Luik CI, Dunning JD, Povel JA, Rutten AP, Volvics A. No-touch isolation technique in colon cancer: a controlled prospective trial. Br J Surg 1988; 75: 409-415

21 Fujita S, Kudo N, Akasu T, Moriya Y. Detection of cytokeratin 19 and 20 mRNA in peripheral and mesenteric blood from colorectal cancer patients and their progeny. Int J Colorectal Dis 2001; 16: 141-146

22 Guller U, Zajac P, Schinnerer A, Bosc B, Vorburger S, Zuber M, Spagnoli GC, Oertli D, Maurer R, Metzger U, Harder F, Heberer M, Marti WR. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236: 768-775; discussion 775-776.

23 Hayashi N, Egami H, Kai M, Kurusu Y, Takano S, Ogawa M. No-touch isolation technique reduces intraoperative shedding of tumor cells into the portal vein during resection of colorectal cancer. Surgery 1999; 125: 369-374

24 Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 1982, 69: 613-616

25 Law WL, Chu KW. Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients. Ann Surg 2004; 240: 260-268

26 Eker WE, Thaler HT, Cranor ML, Polyan T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 1995; 181: 335-346

27 MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet 1993; 341: 457-460

28 Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet 2000; 356: 93-96

29 Arenas RB, Fichera A, Mhoon D, Michelassi F. Total mesenteric excision in the surgical treatment of rectal cancer: a prospective study. Arch Surg 1998; 133: 608-611; discussion 611-612

30 Tocchi A, Mazzoni G, Lepre L, Liotta G, Costa G, Agostini N, Miccini M, Scuccia L, Frati G, Tagliacozzo S. Total mesorectal excision and low rectal anastomosis for the treatment of rectal cancer and prevention of pelvic recurrences. Arch Surg 2001; 136: 216-220

31 Moore HG, Riedel E, Minsky BD, Saltz L, Paty P, Wong D, Cohen AM, Guillem JG. Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol 2003; 10: 80-85

32 Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002; 89: 1142-1149

33 Group. TCOoSTS. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2002; 347: 2050-2059

34 Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM, Visa J. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet 2002; 359: 2224-2229

35 Jacobs M, Verdeja JC, Goldstein HS. Minimally invasive colon resection (laparoscopic colectomy). Surg Laparosc Endosc 1991; 1: 144-150

36 Braga M, Vignali A, Gianiotti L, Zuliani W, Radaelli G, Guarin P, Dellobana P, Di Carlo V. Laparoscopic versus open colorectal surgery: a randomized trial on short-term outcome. Ann Surg 2002; 236: 759-766; discussion 767

37 Chapman AE, Levitt MD, Hewett P, Woods R, Sheiner H, Madder GJ. Laparoscopic-assisted resection of colorectal malignancies: a systematic review. Ann Surg 2001; 234: 590-606

38 Mathew G, Watson DJ, Rofe AM, Ellis T, Jamieson GG. Adverse impact of pneumoperitoneum on intraperitoneal implantation and growth of tumour cell suspension in an experimental model. Aust N Z J Surg 1997; 67: 289-292

39 Wysocki A. [Does the laparoscopic technique influence the intraperitoneal tumor dissemination?] Przegl Lek 2000; 57: 195-197

40 Jingli C, Rong C, Rubai X. Influence of colorectal laparoscopic surgery on dissemination and seeding of tumor cells. Surg Endosc 2006; 20: 1759-1761

www.wjgnet.com
Radiofrequency ablation of malignant liver cancer. *Lancet Oncol* 2006; 7: 291

Gayowski TJ, Iwatsuki S, Madariaga JR, Selby R, Todo S, Irish W, Starzl TE. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. *Surgery* 1994; 116: 703-710; discussion 710-711

Beckerts KT, Holscher AH, Thorban S, Bollschweiler E, Siewert JR. Significance of lymph node involvement at the hepatic hilum in the resection of liver metastases. *Br J Surg* 1997; 84: 1081-1084

Bolton JS, Fuhrman GM. Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. *Ann Surg* 2000; 231: 743-751

Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, Lillemoe KD, Yeo CJ, Cameron JL. Trends in long-term survival following liver resection for hepatic colorectal metastases. *Ann Surg* 2002; 235: 759-766

Van Ooijen B, Wiggers T, Meijer S, van de Heijde MN, Koosje TM, van de Velde CJ, Obertop H, Gouma DJ, Bruggink ED, Lange JF. Hepatic resections for colorectal metastases in The Netherlands. A multiinstitutional 10-year study. *Cancer* 1992; 70: 28-34

Wanebo HJ, Chu QD, Vezeridis MP, Soderberg C. Patient selection for hepatic resection of colorectal metastases. *Arch Surg* 1996; 131: 322-329

Lind DS, Parker GA, Horsley JS 3rd, Korstein MJ, Neifeld JP, Bear HD, Lawrence W Jr. Formal hepatic resection of colorectal liver metastases. Flowit and prognosis. *Ann Surg* 2002; 215: 677-685; discussion 683-684

Rees M, Tekkis PP, Welsh FK, O’Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. *Ann Surg* 2008; 247: 125-135

Minagawa M, Yamamoto J, Miwa S, Sakamoto Y, Kokudo N, Kosuge T, Miyagawa S, Makuch M. Selection criteria for simultaneous resection in patients with synchronous liver metastasis. *Arch Surg* 2006; 141: 1006-1012; discussion 1013

Cady B, Stone MD, McDermott WV Jr, Jenkins RL, Bothe A Jr, Lavin PT, Lovett EJ, Steele GD Jr. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. *Ann Surg* 1992; 217: 561-568; discussion 568-569

Curley SA. Radiofrequency ablation of malignant liver tumors. *Oncologist* 2001; 6: 14-23

Bilchik AJ, Wiggins T, Allegro DP. Radiofrequency ablation of unresectable hepatic malignancies: lessons learned. *Oncologist* 2001; 6: 24-33

Abdalla EK, Vauthney JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K, Curley SA. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablative treatment for colorectal liver metastases. *Ann Surg* 2004; 239: 818-825; discussion 825-827

Elias D, Goharian A, El Otmany A, Taieb J, Vuillard P, Lasser P, de Baere T. Usefulness of intraoperative radiofrequency thermoablation of liver tumours associated or not with hepatocarcinoma. *Eur J Surg Oncol* 2000; 26: 763-769

Pawlik TM, Izzo F, Cohen DS, Morris JS, Curley SA. Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. *Ann Surg Oncol* 2003; 10: 1059-1069

De Baere T, Elias D, Dromain C, Din MG, Kuoch V, Ducreu M, Boige V, Lassau N, Marteau V, Lasser P, Roche A. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. *AJR Am J Roentgenol* 2000; 175: 1619-1625

Vogelsang H, Haas S, Hierholzer C, Berger U, Siewert JR, Prauer H. Factors influencing survival after resection of pulmonary metastases from colorectal cancer. *Br J Surg* 2004; 91: 1066-1071

Pfannschmidt J, Muley T, Hoffmann H, Dienemann H.
Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003; 126: 732-739.

Higashiyama M, Kodama K, Higaki N, Takami K, Murata K, Kameyama M, Yokouchi H. Surgery for pulmonary metastases from colorectal cancer: the importance of prethoracotomy serum carcinoembryonic antigen as an indicator of prognosis. Int J Thoracic Cardiovasc Surg 2003; 51: 289-296.

Ishikawa K, Hashiguchi Y, Mochizuki H, Otsuki Y, Ueno H. Extranodal cancer deposit at the primary tumour site and the number of pulmonary lesions are useful prognostic factors after surgery for colorectal lung metastases. Dis Colon Rectum 2003; 46: 629-636.

Ike H, Shimada H, Ohki S, Togo S, Yamaguchi S, Ichikawa Y. Results of aggressive resection of lung metastases from colorectal carcinoma detected by intensive follow-up. Dis Colon Rectum 2002; 45: 468-473; discussion 473-475.

Saito Y, Omiya H, Kohn K, Kobayashi T, Ito K, Teramachi M, Sasaki M, Suzuki H, Takah H, Nakade M. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment. J Thoracic Cardiovasc Surg 2002; 124: 1007-1013.

Rena O, Casadio C, Viano F, Cristofori R, Ruffini E, Filosso PL, Maggi G. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg 2002; 21: 906-912.

Sakamoto T, Tsutoba N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M. Pulmonary resection for metastases from colorectal cancer. Chest 2001; 119: 1069-1072.

Regnard JF, Grunewald D, Spaggiari L, Girard P, Elias D, Ducreux M, Baldeyrou P, Levasseur P. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998; 66: 214-218; discussion 218-219.

McAfee MK, Allen MS, Trastek VF, Istrup DM, Deschamps C, Patiroleo PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992; 53: 780-785; discussion 785-786.

Girard P, Ducreux M, Baldeyrou P, Rougier P, Le Chevalier T, Bougara J, Lasser P, Gayet B, Ruffie P, Grunenwald D. Surgery for lung metastases from colorectal cancer: analysis of prognostic factors. J Clin Oncol 1996; 14: 2047-2053.

Inoue M, Katakai Y, Nakagawa K, Fujiiwara K, Kusumoto Y, Tanaka T, Kusumoto Y, Asamura H. Pulmonary resection for metastatic colorectal cancer. Ann Thorac Surg 2002; 73: 380-383.

Goya T, Miyazawa N, Kondo H, Tsuchiya R, Naruke T, Suematsu K. Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up. Cancer 1989; 64: 1418-1421.

Van Halteren HK, Van Geel AN, Hart AA, Zoetmulder FA. Pulmonary resection for metastases of colorectal origin. Chest 1995; 107: 1526-1531.

Okumura S, Kondo H, Tsutou M, Nakayama H, Asamura H, Tsuchiya R, Naruke T. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996; 112: 867-874.

Yano T, Hara N, Ichinose Y, Yokoyama H, Miura T, Ohta M. Results of pulmonary resection of metastatic colorectal cancer and its application. J Thoracic Cardiovasc Surg 1993; 106: 872-879.

Izawa T, Suzuki M, Yoshida S, Motohashi S, Yasufuku K, Iyoda A, Shihuya K, Hiroshima K, Nakatani Y, Fujisawa T. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg 2006; 82: 254-260.

Party, MRCRCW. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party. Lancet 1996; 348: 1605-1610.

Trial. SRC. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med 1997; 336: 980-987.

Mariani CA, Nagtegaal ID, Klein Kranenburg E, Hermans J, van der Velde C, Leer JW, van Krieken JH. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19: 1976-1984.

Bjukko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Pudełko M, Kryj M, Olezdi J, Szmeja J, Sluszniai J, Serkies K, Kluday J, Pamucka M, Kukolowicz P. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24.

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosavljevic-Luc L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123.

Sauer R, Becker H, Hohenberger W, Rodel C, Wittkeind C, Fietkau R, Martus P, Tschmeltisch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidbauer H, Raab R. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740.

Glynn-Jones R, Sebag-Montefiore D, Maughan TS, Falk SJ, McDonald AC. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol 2006; 17: 50-56.

Craen I, Ceillin A, Cooper R, Melker A, Byrne P, Sebag-Montefiore D. Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. Br J Cancer 2007; 97: 1333-1337.

Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002; 54: 403-408.

Hospers GA, Punt CJ, Tessalear MA, Cats A, Havenga K, Leer JW, Marijnens CA, Janssen EP, Van Krieken HH, Wiggers T, Van de Velde CJ, Mulder NH. Preoperative chemoradiation with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 2007; 14: 2773-2779.

Glynn-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? J Clin Oncol 2006; 24: 361-371.

Rodel C, Grabenbauer GG, Papadopoulos T, Hohenberger W, Schmoll HJ, Sauer R. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104.

Moosmann N, Laessig D, Michaeily H, Schulz C, Heinemann V. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie 2007; 30: 509-512.

Giantonio BJ, Catalano PJ, Mersonol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFIRI4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544.

Reddy SK, Morse MA, Hurwitz HI, Bendell JC, Gan TJ, Hill SE, Clary BM. Addition of bevacizumab to irinotecan and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 2008; 206: 96-106.

D’Angelica M, Kornprat P, Gonen M, Chung KY, Jarnagin WR, DeMatteo RP, Fong Y, Kemeny N, Blumgart LH, Saltz LB. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab.
a matched case-control study. Ann Surg Oncol 2007; 14: 759-765

108 Manfredi S, Bouvier AM, Lepage C, Hatem C, Dancourt V, Faivre J. Incidence and patterns of recurrence after resection for cure of colorectal cancer in a well defined population. Br J Surg 2006; 93: 1115-1122

109 Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemotherapy Pharmacol 1999; 43 Suppl: S15-S25

110 Nduka CC, Darzi A. Port-site metastasis in patients undergoing laparoscopy for gastrointestinal malignancy. Br J Surg 1997; 84: 583

111 McCarthy RA, Hay ED. Collagen I, laminin, and tenascin: ultrastructure and correlation with avian neural crest formation. Int J Dev Biol 1991; 35: 437-452

112 Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25

113 Phillips DR, Charo IF, Scarborough RM. GPIIb-IIIa: the differential ability to inhibit proliferation and induce apoptosis of hematopoietic and epithelial cells. Br J Pharmacol 1997; 124: 139-147

114 Eckman L, Huang GT, Smith JR, Morzycka-Wroblewska E, Kagnoff MF. Increased transcription and coordinate stabilization of mRNAs for secreted immunoglobulin alpha heavy chain and kappa light chain following stimulation of immunoglobulin A expressing B cells. J Biol Chem 1994; 269: 33102-33108

115 Yazawa K, Tsuno NH, Kitayama J, Kawai K, Okaji Y, Asakage M, Sunami E, Kaisaki S, Hori N, Watanabe T, Takahashi K, Nagawa H. Selective inhibition of cyclooxygenase-2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of beta1 integrin. Cancer Sci 2005; 96: 93-99

116 Church RD, Fleshman JW, McLeod HL. Cyclooxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003; 90: 1055-1067

117 Lee SW, Gleason NR, Bessler M, Whelan RL. Peritoneal irrigation with povidone-iodine solution after laparoscopic-assisted splenectomy significantly decreases port-tumor recurrence in a murine model. Dis Colon Rectum 1999; 42: 319-326

118 Watson DI, Ellis T, Leeder PC, Neuhaus SJ, Dodd T, Jamieson GG. Excision of laparoscopic port sites increases the likelihood of wound metastases in an experimental model. Surg Endosc 2003; 17: 83-85

119 Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000; 6: 4064-4068

120 Gianotti T, Cortesi C, Bechi P, Fantappie O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R, Masini E. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 2001; 121: 1339-1347

121 Waskiewich C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 2002; 62: 2029-2033

122 Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002; 531: 278-284

123 Grzesiak JJ, Pierschbacher MD. Shifts in the concentrations of magnesium and calcium in early porcine and rat wound fluids activate the cell migratory response. J Clin Invest 1995; 95: 227-233

124 Ebert EC. Mechanisms of colon cancer binding to substratum and cells. Dig Dis Sci 1996; 1: 1531-1536

125 Thamilselvan V, Fomby M, Walsh M, Basson MD. Divalent cations modulate human colon cancer cell adhesion. J Surg Res 2003; 110: 255-265

126 Van der Voort van Zyp J, Conway WC, Thamilselvan V, Polin L, Basson MD. Divalent cations influence colon cancer cell adhesion in a murine transplantable tumor model. Am J Surg 2005; 190: 701-707

127 Fidler IJ. The pathogenesis of cancer metastasis: the `seed and soil' hypothesis revisited. Nat Rev Cancer 2003; 3: 453-458

128 Dregelid E, Svendsen E. Endothelial cell injury in human saphenous veins after manipulation and tweezing grasping. J Cardiovasc Surg (Torino) 1988; 29: 464-469

129 Frauenfelder FT, Boozman FW, Wilson RS, Thomas AH. No-touch technique for intraocular malignant melanomas. Arch Ophthalmol 1977; 95: 1616-1620

130 Basson MD, Yu CF, Herden-Kirchoff O, Ellermeier M, Sanders MA, Merrell RC, Sumpio BE. Effects of increased ambient pressure on colon cancer cell adhesion. J Cell Biochem 2000; 78: 47-61

131 Thamilselvan V, Patel A, van der Voort van Zyp J, Basson MD. Colon cancer cell adhesion in response to Src kinase activation and actin-cytoskeleton by non-laminar shear stress. J Cell Biochem 2004; 92: 361-371

132 Van der Voort van Zyp J, Thamilselvan V, Walsh M, Polin L, Basson MD. Extracellular pressure stimulates colon cancer cell adhesion in vitro and to surgical wounds by Src (sarcoma protein) activation. Am J Physiol Cell Physiol 2004; 288: 467-473

133 Shiratsuchi H, Ellner JJ, Basson MD. Extracellular-regulated kinase activation regulates replication of Mycobacterium avium intracelluarly in primary human monocytes. Cell Tissue Res 2008; 332: 237-244

134 Longhurst CM, Jennings LK. Integrin-mediated signal transduction. Cell Mol Life Sci 1998; 54: 514-526

135 Kim M, Javed NH, Yu JG, Christofi F, Cooke HJ. Mechanical stimulation activates Gqalpha signaling pathways and 5-hydroxytryptamine release from human carcinoid BON cells. J Clin Invest 2001; 108: 1051-1059

136 Thamilselvan V, Basson MD. Pressure activates colon cancer cell adhesion by inside-out focal adhesion complex and actin cytoskeletal signaling. Gastroenterology 2004; 126: 8-18

137 Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002; 4: 191-194

138 Kermorgant S, Apicario T, Dessirier V, Lewin MJ, Lehy T. Hepatocyte growth factor induces colon cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for P13 kinase and PKC involvement. Carcinogenesis 2001; 22: 1035-1042

139 Coffey JC, Wang JH, Smith MJ, Laing A, Bouchier-Hayes D, Cotter TG, Redmond HP. Phosphoinositide 3-kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 2005; 280: 20968-20977

140 Shayesteh L, Liu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102

141 Phillips WA, St Clair F, Munday AD, Thomas RJ, Mitchell CA. Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 1998; 83: 41-47

142 Thamilselvan V, Craig DH, Basson MD. FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 2007; 21: 1730-1741

143 Wang S, Basson MD. Identification of functional domains in AKT responsible for distinct roles of AKT isoforms in pressure-stimulated cancer cell adhesion. Exp Cell Res 2008; 314: 286-296

144 Thamilselvan V, Basson MD. The role of the cytoskeleton in differentially regulating pressure-mediated effects on malignant colonocyte focal adhesion signaling and cell...
adhesion. 

Van Zyp JV, Conway WC, Craig DH, van Zyp NV, Thamilselvan V, Basson MD. Extracellular pressure stimulates tumor cell adhesion in vitro by paxillin activation. Cancer Biol Ther 2006; 5: 1169-1178

Conway WC, Van der Voort van Zyp J, Thamilselvan V, Walsh MF, Crowe DL, Basson MD. Paxillin modulates squamous cancer cell adhesion and is important in pressure-augmented adhesion. J Cell Biochem 2006; 98: 1507-1516

Craig DH, Haimovich B, Basson MD. Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction. Am J Physiol Cell Physiol 2007; 293: C1862-C1874

Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, Ohnishi M, Ohyama T, Shingaki S, Kaji M, Saku Y, Takagi R. Identification of potential biomarkers of lymph node metastasis in oral squamous cell carcinoma by cDNA microarray analysis. Int J Cancer 2003; 106: 683-689

Azuma K, Tanaka M, Uekita T, Inoue S, Yokota J, Ouchi Y, Sakai R. Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene 2005; 24: 4754-4764

Prados J, Melguizo C, Fernandez JE, Aranega AE, Alvarez L, Aranega A. Actin, tropomyosin and alpha-actinin as markers of differentiation in human rhabdomyosarcoma cell lines induced with dimethyl sulfoxide. Cell Mol Biol (Noisy-le-grand) 1993; 39: 525-536

S- Editor Zhong XY  L- Editor Li M  E- Editor Zhang WB